Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. ADGM
ADGM logo

ADGM Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Adagio Medical Holdings Inc (ADGM) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.960
1 Day change
52 Week Range
2.870
Analysis Updated At
2026/03/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Adagio Medical Holdings Inc (ADGM) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock exhibits weak financial performance, no positive trading signals, and a bearish technical outlook. Additionally, there are no positive news catalysts or significant insider or congressional trading activity to support a buy decision.

Technical Analysis

The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 38.588, and moving averages are converging, showing no clear trend. The stock is trading below key support levels, with a bearish price trend expected in the short and medium term (-5.4% in the next week, -14.67% in the next month).

Positive Catalysts

  • Hedge funds are buying, with a 1972.62% increase in the last quarter.

Neutral/Negative Catalysts

  • No recent news, poor financial performance with revenue dropping to zero (-100% YoY), and gross margin also at zero (-100% YoY). The stock has a high likelihood of further price declines in the short term.

Financial Performance

In Q3 2025, revenue dropped to $0 (-100% YoY), gross margin dropped to 0 (-100% YoY), net income improved to -$10,118,000 (+118.58% YoY), and EPS increased to -0.66 (+106.25% YoY). Overall, the financials show significant weaknesses, particularly in revenue and gross margin.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data available.

Wall Street analysts forecast ADGM stock price to rise
1 Analyst Rating
Wall Street analysts forecast ADGM stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.960
sliders
Low
4
Averages
4
High
4
Current: 0.960
sliders
Low
4
Averages
4
High
4
Lake Street
initiated
$4
AI Analysis
2025-12-02
Reason
Lake Street
Price Target
$4
AI Analysis
2025-12-02
initiated
Reason
Lake Street initiated coverage of Adagio Medical with a Buy rating and $4 price target. Adagio, which recently released top-line pivotal clinical data for its ultra-low temperature cryoablation vCLAS catheter for the "underserved" ventricular tachycardia ablation market, is approaching several "important value-creating catalysts," including the full FULCRUM-VT clinical data release due in the first half of 2026 and FDA approval that the firm expects in the second half of 2026, the analyst tells investors.

People Also Watch